Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Treasury Shares: 2017-2025

Historic Treasury Shares for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $5.2 million.

  • Denali Therapeutics' Treasury Shares rose 29.62% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 29.62%. This contributed to the annual value of $4.1 million for FY2024, which is 13.57% up from last year.
  • Per Denali Therapeutics' latest filing, its Treasury Shares stood at $5.2 million for Q3 2025, which was up 0.97% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Treasury Shares ranged from a high of $5.2 million in Q3 2025 and a low of $2.6 million during Q3 2021.
  • Over the past 3 years, Denali Therapeutics' median Treasury Shares value was $4.1 million (recorded in 2024), while the average stood at $4.3 million.
  • Data for Denali Therapeutics' Treasury Shares shows a peak YoY skyrocketed of 64.78% (in 2021) over the last 5 years.
  • Over the past 5 years, Denali Therapeutics' Treasury Shares (Quarterly) stood at $2.6 million in 2021, then increased by 26.64% to $3.3 million in 2022, then climbed by 9.14% to $3.6 million in 2023, then increased by 13.57% to $4.1 million in 2024, then rose by 29.62% to $5.2 million in 2025.
  • Its Treasury Shares stands at $5.2 million for Q3 2025, versus $5.1 million for Q2 2025 and $4.8 million for Q1 2025.